These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 28059452)

  • 1. Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.
    Xiang D; Cheng Z; Liu H; Wang X; Han T; Sun W; Li X; Yang W; Chen C; Xia M; Liu N; Yin S; Jin G; Lee T; Dong L; Hu H; Wang H; Ding J
    Hepatology; 2017 May; 65(5):1566-1580. PubMed ID: 28059452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway.
    Cheng Z; Lei Z; Yang P; Si A; Xiang D; Zhou J; Hüser N
    Gene; 2019 Feb; 684():95-103. PubMed ID: 30359743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
    Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
    Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged inhibition of class I PI3K promotes liver cancer stem cell expansion by augmenting SGK3/GSK-3β/β-catenin signalling.
    Liu F; Wu X; Jiang X; Qian Y; Gao J
    J Exp Clin Cancer Res; 2018 Jun; 37(1):122. PubMed ID: 29940988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
    Li B; Liu D; Yang P; Li HY; Wang D
    Gene; 2019 Jul; 707():78-85. PubMed ID: 31075412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.
    Liu C; Li J; Wang W; Zhong X; Xu F; Lu J
    Cell Cycle; 2020 May; 19(10):1077-1088. PubMed ID: 32286127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of cancer stem cells via β-catenin contributing to the tumorigenesis of hepatocellular carcinoma.
    Pandit H; Li Y; Li X; Zhang W; Li S; Martin RCG
    BMC Cancer; 2018 Aug; 18(1):783. PubMed ID: 30075764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc finger protein X-linked promotes expansion of EpCAM
    Wang C; Fu SY; Wang MD; Yu WB; Cui QS; Wang HR; Huang H; Dong W; Zhang WW; Li PP; Lin C; Pan ZY; Yang Y; Wu MC; Zhou WP
    Mol Oncol; 2017 May; 11(5):455-469. PubMed ID: 28156061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAF enhances cancer stem cell properties via β-catenin signaling in hepatocellular carcinoma.
    Li M; Mu XD; Song JR; Zhai PT; Cheng Y; Le Y; Li ZB
    Cell Cycle; 2021 May; 20(10):1010-1020. PubMed ID: 33970778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-194 inhibits liver cancer stem cell expansion by regulating RAC1 pathway.
    Ran RZ; Chen J; Cui LJ; Lin XL; Fan MM; Cong ZZ; Zhang H; Tan WF; Zhang GQ; Zhang YJ
    Exp Cell Res; 2019 May; 378(1):66-75. PubMed ID: 30844391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-365 regulates liver cancer stem cells via RAC1 pathway.
    Jiang ZB; Ma BQ; Liu SG; Li J; Yang GM; Hou YB; Si RH; Gao P; Yan HT
    Mol Carcinog; 2019 Jan; 58(1):55-65. PubMed ID: 30182377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
    Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
    Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
    Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
    Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.
    Chua HH; Tsuei DJ; Lee PH; Jeng YM; Lu J; Wu JF; Su DS; Chen YH; Chien CS; Kao PC; Lee CN; Hu RH; Ni YH; Chang MH
    Hepatology; 2015 Nov; 62(5):1480-96. PubMed ID: 26185016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lnc-β-Catm elicits EZH2-dependent β-catenin stabilization and sustains liver CSC self-renewal.
    Zhu P; Wang Y; Huang G; Ye B; Liu B; Wu J; Du Y; He L; Fan Z
    Nat Struct Mol Biol; 2016 Jul; 23(7):631-9. PubMed ID: 27239797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling.
    Fan Z; Duan J; Wang L; Xiao S; Li L; Yan X; Yao W; Wu L; Zhang S; Zhang Y; Li Y; Zhu X; Hu Y; Zhang D; Jiao S; Xu X
    Cancer Lett; 2019 May; 450():132-143. PubMed ID: 30849480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
    Lu WJ; Chua MS; Wei W; So SK
    Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.
    Xu Q; Xu HX; Li JP; Wang S; Fu Z; Jia J; Wang L; Zhu ZF; Lu R; Yao Z
    Oncotarget; 2017 Mar; 8(10):16972-16987. PubMed ID: 28199981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.